Survival in ovarian cancer patients by histology and family history

Acta Oncologica

Volumn 47, Issue 6, 2008, Pages 1133-1139

  Ji, Jianguang ^a   Forsti, Asta ^a,b   Sundquist, Jan ^a   Lenner, Per ^c   Hemminki, Kari ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; EPITHELIUM TUMOR; FAMILY HISTORY; FEMALE; GERM CELL TUMOR; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICAL HISTORY TAKING; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; ODDS RATIO; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SWEDEN;

EID: 51149108542     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701784544     Document Type: Article

References (25)

1. Tavassoli F, Devilee P. Tumours of the breast and female genital organs. In: Pathology and Genetics. Lyon: IARC; 2003.
2. Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2006;20:339-62.
3. Holschneider CH, Berek JS. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
4. Cadron I, Amant F, Van Gorp T, Neven P, Leunen K, Vergote I. The management of borderline tumours of the ovary. Curr Opin Oncol 2006;18:488-93.
5. Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78:21-7.
6. Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, et al. Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol 1989;34:88-93.
7. Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N, Watari H, et al. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 2003;13:776-84.
8. Skirnisdottir I, Seidal T, Karlsson MG, Sorbe B. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol 2005;26:177-83.
9. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9.
10. Hemminki K, Sundquist J, Bermejo J. How common is familial cancer? Ann Oncol 2007.
11. Zweemer RP, Verheijen RH, Gille JJ, van Diest PJ, Pals G, Menko FH. Clinical and genetic evaluation of thirty ovarian cancer families. Am J Obstet Gynecol 1998;178:85-90.
12. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
13. Hemminki K, Forsti A, Lorenzo Bermejo J. Etiologic impact of known cancer susceptibility genes. Mutat Res 2007.
14. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 1999;59:868-71.
15. Zweemer RP, Verheijen RH, Coebergh JW, Jacobs IJ, van Diest PJ, Gille JJ, et al. Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol 2001;98:219-23.
16. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden. J Clin Oncol 1998;16:397-404.
17. Hemminki K, Ji J, Forsti A, Sundquist J, Lenner P. Survival in breast cancer is familial. Breast Cancer Res Treat 2007.
18. Hemminki K, Granström C, Sundquist J, Lorenzo Bermejo J. The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. Hered Cancer Clin Pract 2006;4:186-92.
19. SAS Institute. SAS/STAT 9.1 User's Guideed. Cary: SAS Publishing, 2004.
20. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003;101:885-91.
21. Silverberg SG. Prognostic significance of pathologic features of ovarian carcinoma. Curr Top Pathol 1989;78:85-109.
22. National Cancer Institute. SEER survival monograph. 2007.
23. Tohya T. Ovarian sex cord-stromal tumor, unclassified: Case report of endocrinologic findings and review of the literature. Int J Gynecol Cancer 2005;15:1153-5.
24. Navarini R, Pineda RL. Malignant mixed mullerian tumors of the ovary. Curr Opin Obstet Gynecol 2006;18:20-3.
25. Aparicio J, Germa JR, Garcia del Muro X, Maroto P, Arranz JA, Saenz A, et al. Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005;23:8717-23.